Care for Skin Diseases
Chronic skin conditions, such as Psoriasis, are characterized by various symptoms including flaking, inflammation, and thick, white, silvery, or red patches of skin. OWC’s topical ointment was developed to alleviate these signs and symptoms.
OWC conducted extensive pre-clinical research that showed that the ointment inhibits keratocyte proliferation, which is a central aspect in Psoriasis. The study also showed lowering of various cytokines associated with inflammation in general (Il-8), and more specifically with Psoriasis (IL-33).
OWC has performed a 6-week safety study on 26 healthy subjects in one of Israel’s leading academic medical centers. The safety study demonstrated that the ointment remained topical with little to no penetration to the blood system (and thus induced no psychoactive side effects), and with nearly no local side effects.
OWC is currently in the process of obtaining all requisite approvals to initiate an efficacy study for its ointment formulation on Psoriasis patients.
RELATED ARTICLES
OWC Pharmaceutical Research Corp Successfully Tests Unique, Innovative Delivery Formulation Aimed at Multiple Myeloma Therapy.
Our newly developed, highly concentrated formulation, OWC-1808, was administered in vivo for the first time and was found to be safe and tolerable. This formulation will allow the delivery of very high doses of CBD and THC with exceptional bioavailability, and will be directed initially at our ongoing program for treating Multiple Myeloma.
OWC Pharmaceutical Research Corp. to report progress in clinical trials for ointment care for skin diseases.
The first ever safety study of cannabis-based topical ointment, conducted at Sheba Academic Medical Center, is close to completion as the last healthy volunteer started the treatment three weeks ago. The study is expected to be completed by the end of December 2018.
OWC Pharmaceutical Research Corp Completes Development of Next Generation Orally-Disintegrating Tablet.
OWC Pharmaceutical has completed the pre-clinical development of its next generation, orally-disintegrating tablet containing cannabis extract with specific amounts of the cannabinoids tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”). The tablet is targeted at different indications and will be available in various ratios of THC to CBD and various doses of these actives.
